# Syneron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syneron

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Latest round: Series A (Nov 19, 2024)
- Investors on record: 3

## About

Established in 2022 and based in Guangzhou, China, Syneron operates as an AI pharmaceutical company that focuses on the development of artificial intelligence synthetic peptide new drugs. Xiao Zhang, the company's founder and CEO, is also the managing director of China Renaissance Capital. He graduated from Rutgers University in the United States and worked at CITIC Construction Investment Capital. In November 2024, Syneron closed a series A funding.

The company's main business is the research and development of new synthetic peptide drugs using artificial intelligence. It has AI+synthetic peptide drug research and development platform SynCore. SynCore applies AI to the design, screening, synthesis, characterization, and optimization of synthetic peptide drugs. The platform can be used in the fields of innovative peptide drug research and development, enzyme engineering, etc.

The company generates revenue by providing new synthetic peptide drugs.

The company will use the series A funding to accelerate the research and development of synthetic peptide drugs.

## Funding rounds

- Series A, Nov 19, 2024 — Lilly Asia Ventures, Astra Zeneca CICC Healthcare Venture Capital Fund, Beijing Xinneng Venture Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series A
- Beijing Xinneng Venture Capital (https://capitalatlas.ai/funds/beijing-xinneng-venture-capital) — Series A